BIMINI Biotech is a preclinical stage company developing novel first-in-class small molecule therapeutics in oncology with a focus on lymphomas and leukemia, malignancies with a strong unmet need. BIMINI’s approach is based on pioneering research by Institute of Oncology Research (CH) that targets Wiskott Aldrich Syndrome protein (or WASp), an actin nucleation related protein expressed exclusively in hematopoietic cells. The actin cytoskeleton is a network of fibers and tubes that gives the cell firmness, shape and mobility and is important for cell division. Depending on the type of tumor, activation or inhibition of the protein can elicit a strong anti-cancer effect. BIMINI has a portfolio of two proprietary agents that can inhibit or activate WASp. Our approach has shown promising in vitro and in vivo results.
Our WASp activator (BM-011) over-activates the auto-inhibited form of WASp causing uncontrolled actin polymerization. WASp overactivation causes genomic instability resulting in apoptosis of specifically lymphoma cells.
Target indications include Diffuse large B-cell lymphoma (DLBCL) and Mantle cell lymphoma (MCL). The compounds show strong synergism with FDA-approved drugs in hematological cancers and are active in resistant cell lines, opening up the potential of second line therapy for refractory or relapsed cases.
Our WASp inhibitor (BM-013) downregulates the WASp concentration and function by enhancing degradation of the protein, thereby inhibiting the proliferation specifically of leukemic cells.
Target indications include Acute myeloid leukemia (AML) and T-Cell Lymphoblastic Leukemia (T-ALL).
We are always open to discuss potential collaborations to bring innovative oncology therapeutics closer to the patient. Please feel free to contact us.